A prodrug composition is provided which includes a pharmaceutical species and an amino acid having a covalent bond to the pharmaceutical species. The pharmaceutical species is characterized by bioavailability of 30% or less and a molecular weight in the range of 100-1000 Daltons. The composition is characterized further in that the pharmaceutical species is not acyclovir, ganciclovir, BRL44385, or penciclovir. Also described is an inventive method of delivering a pharmaceutical species to an individual including the step of orally administering an inventive prodrug to an individual. In one embodiment the prodrug includes a pharmaceutical species characterized by bioavailability of 30% or less, wherein the pharmaceutical species has a molecular weight in the range of 100-1000 Daltons. The inventive prodrug is transported from the gastrointestinal lumen by a specific transporter and is enzymatically cleaved to yield the pharmaceutical species, such that the pharmaceutical species is delivered to the individual.
提供了一种前药组合物,其中包括一种药用物种和与该药用物种具有共价键的
氨基酸。该药用物种的
生物利用度为30%或更低,分子量在100-1000道尔顿的范围内。该组合物的特征进一步在于,该药用物种不是
阿昔洛韦、甘
氨鸟苷、BRL44385或者喷昔洛韦。还描述了一种将药用物种传递给个体的创新方法,其中包括口服给个体一种创新前药的步骤。在一个实施例中,前药包括一种
生物利用度为30%或更低的药用物种,该药用物种的分子量在100-1000道尔顿的范围内。该创新前药通过特定转运体从胃肠腔转运,并经酶解裂解以产生药用物种,从而将药用物种传递给个体。